October 27, 2022
1 min read
Zaffagnini reports receiving personal fees from I+ and grants from Fidia Farmaceutici, CartiHeal, IGEA Clinical Biophysics, Biomet and Kensey Nash. Please see the study for all other authors’ relevant financial disclosures.
Results showed intra-articular injection of microfragmented adipose tissue or platelet-rich plasma had comparable low numbers of failures and adverse events without signs of disease progression in patients with knee osteoarthritis.
“[Microfragmented adipose tissue] MF-AT seems to represent a suitable strategy for knee OA, especially for more advanced cases,” the authors wrote.
Researchers randomly assigned 118 patients with symptomatic knee OA to receive either a single intra-articular injection of MF-AT or platelet-rich plasma. Researchers collected IKDC subjective scores, KOOS subscales, EuroQol-VAS, EuroQol-5D and VAS for pain prior to the injection and at 1, 3, 6, 12 and 24 months after the injection.
Researchers considered the IKDC subjective score and the KOOS pain subscore at 6 months as the primary outcome. Researchers also evaluated patients’ knees with radiography and high-resolution MRI using the Whole-Organ Magnetic Resonance Imaging Score at baseline and at 6, 12 and 24 months.
Results showed patients in the MF-AT group and the PRP group experienced statistically and clinically significant improvements up to 24 months. Researchers found similar improvements in the IKDC subjective score and the KOOS pain subscore from baseline to 6 months in both groups. Researchers noted no differences in clinical outcomes, adverse events or failures between the two groups, as well as no changes in radiographic and MRI findings after the injection.
At 6 months, more patients in the MF-AT group with moderate to severe OA reached the minimal clinically important difference for the IKDC score vs. the PRP group, according to results.
“Further high-level studies should confirm these findings, investigating the aspects that may influence the response to MF-AT injections, ranging from baseline clinical characteristics to biomarker profiles,” the authors wrote. “Moreover, a proper characterization of this promising biological approach could help us to understand the most suitable way to exploit the adipose tissue potential by comparing its efficacy with other injectable options at longer follow-up.”